FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324291271> ?p ?o ?g. }

• W4324291271 endingPage "046" @default.
• W4324291271 startingPage "040" @default.
• W4324291271 abstract "Levodopa is the most used and effective medication for motor symptoms of Parkinson disease (PD), its long-term use is associated with the appearance of levodopa-induced dyskinesia (LID). Uric acid (UA) is believed to play an important neuroprotective role in PD.To investigate if serum UA levels are related with the presence of LIDs in PD patients. Also, we investigated the associations among UA levels and clinical features of PD.We enrolled 81 PD patients (dyskinesia = 48; no dyskinesia = 33) in the present study. A blood sample was collected to evaluate serum UA levels, clinical evaluation included the following instruments: Montreal Cognitive Assessment (MoCA), Beck Depression Inventory II (BDI-II), MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Hoehn and Yahr (HY), and the sub-item 4.1 of MDS-UPDRS IV (score ≥ 1). Additional relevant clinical information was obtained by a clinical questionnaire.Serum UA levels were lower in the dyskinesia group when compared with the no dyskinesia group. The same result was found in the UA levels of both men and women. The multivariate analysis showed lower uric acid levels were significantly associated with having dyskinesia (odds ratio [OR] = 0.424; 95% confidence interval [CI]: 0.221-0.746; p = 0.005). Additional analysis verified that serum UA levels are inversely correlated with depressive symptoms, disease duration, MDS-UPDRS IV and time spent with dyskinesia. A positive correlation was found with age at onset of PD symptoms.The present study provides a possible role of serum UA levels in LID present in PD patients. A levodopa é a medicação mais utilizada e eficaz para os sintomas motores da doença de Parkinson (DP); seu uso a longo prazo está associado ao aparecimento de discinesia induzida por levodopa (LID). Acredita-se que o ácido úrico desempenhe um importante papel neuroprotetor na DP. Investigar se os níveis séricos de AU estão relacionados com a presença de LID em pacientes com DP. Além disso, investigamos as associações entre os níveis de AU e as características clínicas da DP. MéTODOS: Foram incluídos 81 pacientes com DP (discinesia = 48; sem discinesia = 33) no presente estudo. Uma amostra de sangue foi coletada para avaliar os níveis séricos de AU, a avaliação clínica incluiu os seguintes instrumentos: Avaliação Cognitiva de Montreal (MoCA), Inventário de Depressão de Beck (BDI-II), MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Hoehn and Yahr (HY) e o subitem 4.1 da MDS-UPDRS IV (escore ≥ 1). Informações clínicas relevantes adicionais foram obtidas por meio de um questionário clínico. Os níveis séricos de AU foram menores no grupo com discinesia quando comparados ao grupo sem discinesia. O mesmo resultado foi encontrado nos níveis de AU de homens e mulheres. A análise multivariada mostrou que níveis mais baixos de ácido úrico foram significativamente associados a ter discinesia (odds ratio [OR] = 0,424; intervalo de confiança (IC) de 95%: 0,221–0,746; p = 0,005). Análises adicionais verificaram que os níveis séricos de AU estão inversamente correlacionados com sintomas depressivos, duração da doença, MDS-UPDRS IV e tempo gasto com discinesia. Uma correlação positiva foi encontrada com a idade de início dos sintomas da DP. CONCLUSõES: O presente estudo fornece um possível papel dos níveis séricos de AU na LID presente em pacientes com DP." @default.
• W4324291271 created "2023-03-16" @default.
• W4324291271 creator A5008850750 @default.
• W4324291271 creator A5012332324 @default.
• W4324291271 creator A5018940183 @default.
• W4324291271 creator A5041566745 @default.
• W4324291271 creator A5053549673 @default.
• W4324291271 creator A5055105219 @default.
• W4324291271 creator A5063139586 @default.
• W4324291271 creator A5066885428 @default.
• W4324291271 creator A5084291645 @default.
• W4324291271 date "2023-01-01" @default.
• W4324291271 modified "2023-10-18" @default.
• W4324291271 title "Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease" @default.
• W4324291271 cites W1539334271 @default.
• W4324291271 cites W1967749791 @default.
• W4324291271 cites W1972288745 @default.
• W4324291271 cites W1988184279 @default.
• W4324291271 cites W1988426636 @default.
• W4324291271 cites W1991346604 @default.
• W4324291271 cites W1991530575 @default.
• W4324291271 cites W1999702935 @default.
• W4324291271 cites W2006115845 @default.
• W4324291271 cites W2008560062 @default.
• W4324291271 cites W2014124398 @default.
• W4324291271 cites W2019182054 @default.
• W4324291271 cites W2023819204 @default.
• W4324291271 cites W2037760047 @default.
• W4324291271 cites W2053159042 @default.
• W4324291271 cites W2065197060 @default.
• W4324291271 cites W2068791841 @default.
• W4324291271 cites W2070863068 @default.
• W4324291271 cites W2079595809 @default.
• W4324291271 cites W2097939227 @default.
• W4324291271 cites W2106819531 @default.
• W4324291271 cites W2109572793 @default.
• W4324291271 cites W2112298570 @default.
• W4324291271 cites W2135323430 @default.
• W4324291271 cites W2135978125 @default.
• W4324291271 cites W2149786401 @default.
• W4324291271 cites W2163584809 @default.
• W4324291271 cites W2165758561 @default.
• W4324291271 cites W21769058 @default.
• W4324291271 cites W2290281188 @default.
• W4324291271 cites W2565162239 @default.
• W4324291271 cites W2581916803 @default.
• W4324291271 cites W2598225365 @default.
• W4324291271 cites W2600441637 @default.
• W4324291271 cites W2795021292 @default.
• W4324291271 cites W2896786675 @default.
• W4324291271 cites W2898096496 @default.
• W4324291271 cites W2944852150 @default.
• W4324291271 cites W2969213104 @default.
• W4324291271 cites W3016149614 @default.
• W4324291271 cites W3027435970 @default.
• W4324291271 cites W4294116629 @default.
• W4324291271 doi "https://doi.org/10.1055/s-0043-1761294" @default.
• W4324291271 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36918006" @default.
• W4324291271 hasPublicationYear "2023" @default.
• W4324291271 type Work @default.
• W4324291271 citedByCount "0" @default.
• W4324291271 crossrefType "journal-article" @default.
• W4324291271 hasAuthorship W4324291271A5008850750 @default.
• W4324291271 hasAuthorship W4324291271A5012332324 @default.
• W4324291271 hasAuthorship W4324291271A5018940183 @default.
• W4324291271 hasAuthorship W4324291271A5041566745 @default.
• W4324291271 hasAuthorship W4324291271A5053549673 @default.
• W4324291271 hasAuthorship W4324291271A5055105219 @default.
• W4324291271 hasAuthorship W4324291271A5063139586 @default.
• W4324291271 hasAuthorship W4324291271A5066885428 @default.
• W4324291271 hasAuthorship W4324291271A5084291645 @default.
• W4324291271 hasBestOaLocation W43242912711 @default.
• W4324291271 hasConcept C126322002 @default.
• W4324291271 hasConcept C138496976 @default.
• W4324291271 hasConcept C156957248 @default.
• W4324291271 hasConcept C15744967 @default.
• W4324291271 hasConcept C1862650 @default.
• W4324291271 hasConcept C2776632958 @default.
• W4324291271 hasConcept C2779134260 @default.
• W4324291271 hasConcept C2779483572 @default.
• W4324291271 hasConcept C2779734285 @default.
• W4324291271 hasConcept C2779881121 @default.
• W4324291271 hasConcept C2780304432 @default.
• W4324291271 hasConcept C2780405171 @default.
• W4324291271 hasConcept C44249647 @default.
• W4324291271 hasConcept C71924100 @default.
• W4324291271 hasConcept C83849319 @default.
• W4324291271 hasConcept C90924648 @default.
• W4324291271 hasConceptScore W4324291271C126322002 @default.
• W4324291271 hasConceptScore W4324291271C138496976 @default.
• W4324291271 hasConceptScore W4324291271C156957248 @default.
• W4324291271 hasConceptScore W4324291271C15744967 @default.
• W4324291271 hasConceptScore W4324291271C1862650 @default.
• W4324291271 hasConceptScore W4324291271C2776632958 @default.
• W4324291271 hasConceptScore W4324291271C2779134260 @default.
• W4324291271 hasConceptScore W4324291271C2779483572 @default.
• W4324291271 hasConceptScore W4324291271C2779734285 @default.
• W4324291271 hasConceptScore W4324291271C2779881121 @default.

• next